drugset / Trial / NCT04676516
A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Phase 2
Completed
40 enrolled
Ottawa Hospital Research Institute
GlaxoSmithKline · collabHamilton Health Sciences Corporation · collabLondon Regional Cancer Program, Canada · collabOntario Institute for Cancer Research · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological effects of PRMT5 inhibitor, GSK3326595, in Early Stage Breast Cancer
Timeline
- Start
- 2021-06-08
- Primary completion
- 2022-08-15
- Completion
- 2022-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEMRAMETOSTAT | Small molecule | 200 mg | Oral |